After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Findings for dual-acting are limited to in vitro studies that demonstrate guselkumab binds to CD64, which is expressed on the surface of IL-23 producing cells in an inflammatory monocyte model.

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.

Johnson & Johnson recently announced that TREMFYA® (guselkumab) demonstrated rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement in scalp itch, as ...

A greater number of patients treated with subcutaneous guselkumab induction and maintenance vs placebo achieved clinical remission and endoscopic response at 48 weeks in the Phase 3 GRAVITI study1 ...

Treatment persistence varied by biologic therapy use, sex, and diagnostic codes among patients with psoriasis.

VIENNA — Guselkumab has been shown to be efficacious vs placebo in patients with moderately to severely active Crohn’s disease (CD), regardless of prior biologic therapy exposure, according to ...

On Monday, Johnson & Johnson (NYSE:JNJ) announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn’s ...

Guselkumab Provides Long-Term Relief in Psoriatic Arthritis More than 90% of patients with PsA who received guselkumab every 8 weeks in the DISCOVER-2 trial maintained minimal clinically important ...

At week 16, an IGA score of 0 or 1 was met for guselkumab vs placebo in scalp (75.0% vs 14.5%), face (87.8% vs 28.6%), intertriginous (86.5% vs 28.8%) and genital (78.0% vs 37.5%) psoriasis.

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement ...

About TREMFYA® (guselkumab) Developed by Johnson & Johnson, TREMFYA® is the first approved fully-human, dual-acting monoclonal antibody designed to neutralize inflammation at the ...